{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:17:33Z","timestamp":1775593053226,"version":"3.50.1"},"reference-count":198,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1053\/j.jvca.2025.03.029","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:50:37Z","timestamp":1742464237000},"page":"1795-1814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Cardiovascular Pharmacotherapy. II. Ivabradine, an Inhibitor of the Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel"],"prefix":"10.1053","volume":"39","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.03.029_bib0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1476-5381.1994.tb13025.x","article-title":"Electrophysiological effects of S 16257, a novel sinoatrial node modulator, on rabbit and guinea pig preparations: Comparison with UL-FS 49","volume":"112","author":"Thollon","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0002","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1476-5381.1996.tb15505.x","article-title":"Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells","volume":"118","author":"Bois","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053132","article-title":"Identification of the molecular site of ivabradine binding to HCN4 channels","volume":"8","author":"Bucchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2025.03.029_bib0004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1476-5381.1995.tb14971.x","article-title":"Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats","volume":"115","author":"Gardiner","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","article-title":"Berdeaux A: Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs","volume":"275","author":"Simon","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0006","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Ivabradine Investigators Group. Antianginal and antiichemic effects of ivabradine, and I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0007","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effect angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.03.029_bib0008","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic, stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0009","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ahj.2009.06.008","article-title":"Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION study","volume":"158","author":"Koster","year":"2009","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","article-title":"Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study","volume":"101","author":"Werdan","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0012","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine in patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.03.029_bib0013","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","article-title":"Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients\u2019 treatment with primary percutaneous coronary intervention: A randomized, placebo-controlled, double-blind, pilot study","volume":"2","author":"Steg","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1053\/j.jvca.2025.03.029_bib0015","article-title":"Clinical use of ivabradine in the acute coronary syndrome: A systematic review and narrative synthesis of current evidence","volume":"17","author":"Borovac","year":"2022","journal-title":"Am Heart J Plus"},{"key":"10.1053\/j.jvca.2025.03.029_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0017","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"Spec Feature","key":"10.1053\/j.jvca.2025.03.029_bib0018","first-page":"56","article-title":"Corlanor (Ivabradine), first HCN channel blocker, FDA approved for treatment of patients with heart failure","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1053\/j.jvca.2025.03.029_bib0019","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabridine in patients with heart failure and preserved ejection fraction: The EDIFY randomized, placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/324470a0","article-title":"Characterization of single pacemaker channels in cardiac sino-atrial node cells","volume":"324","author":"DiFrancesco","year":"1986","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.03.029_bib0021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.ph.55.030193.002323","article-title":"Pacemaker mechanisms in cardiac tissue","volume":"55","author":"DiFrancesco","year":"1993","journal-title":"Annu Rev Physiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0022","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/pr.117.014035","article-title":"The hyperpolarization-activated cyclic nucleotide-gated channels: From biophysics to pharmacology of a unique family of ion channels","volume":"69","author":"Sartiani","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0023","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/emboj\/18.9.2323","article-title":"Two pacemaker channels from human heart with profoundly different activation kinetics","volume":"18","author":"Ludwig","year":"1999","journal-title":"EMBO J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0024","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.yjmcc.2008.04.013","article-title":"Molecular basis of funny current (If) in normal and failing human heart","volume":"45","author":"Stillitano","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0025","article-title":"Review: HCN channels in the heart","volume":"18","author":"Depuydt","year":"2022","journal-title":"Curr Cardiol Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.12.023","article-title":"Structures of the human HCN1 hyperpolarization-activated channel","volume":"168","author":"Lee","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.jvca.2025.03.029_bib0027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nature01922","article-title":"Structural basis for modulation and agonist specificity of HCN pacemaker channels","volume":"425","author":"Zagotta","year":"2003","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.03.029_bib0028","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/280235a0","article-title":"How does adrenaline accelerate the heart?","volume":"280","author":"Brown","year":"1979","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.03.029_bib0029","doi-asserted-by":"crossref","first-page":"12908","DOI":"10.1074\/jbc.RA118.002139","article-title":"Mechanical transduction of cytoplasmic-to-transmembrance-domain movements in a hyperpolarization-activated cyclic nucleotide-gated cation channel","volume":"293","author":"Gross","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2025.03.029_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/35081088","article-title":"Molecular mechanism of cAMP modulation of HCN pacemaker channels","volume":"411","author":"Wainger","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.03.029_bib0031","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1073\/pnas.0810332106","article-title":"Control of heart rate by cAMP sensitivity of HCN channels","volume":"106","author":"Alig","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.jvca.2025.03.029_bib0032","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1152\/physrev.00029.2008","article-title":"Hyperpolarization-activated cation channels: From genes to function","volume":"89","author":"Biel","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.2916119","article-title":"Muscarinic modulation of cardiac rate at low acetylcholine concentrations","volume":"243","author":"DiFrancesco","year":"1989","journal-title":"Science"},{"issue":"Suppl 2","key":"10.1053\/j.jvca.2025.03.029_bib0034","first-page":"S366","article-title":"Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care","volume":"142","author":"Panchal","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0035","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0701473","article-title":"The current pacemaker I(f) in single human atrial myocytes and the effect of beta-adrenoceptor and A1-adenosine receptor stimulation","volume":"122","author":"Porciatti","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0036","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/351145a0","article-title":"Direct activation of cardiac pacemaker channels by intracellular cyclic AMP","volume":"351","author":"DiFrancesco","year":"1991","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.03.029_bib0037","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0008-6363(98)00291-0","article-title":"Modulation of the pacemaker current If by beta-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats","volume":"42","author":"Cerbai","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.03.029_bib0038","doi-asserted-by":"crossref","first-page":"H355","DOI":"10.1152\/ajpheart.00154.2009","article-title":"Effects of KCNE2 on HCM isoforms: Distinct modulation of membrane expression and single channel properties","volume":"297","author":"Brandt","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0039","doi-asserted-by":"crossref","first-page":"e1511","DOI":"10.1371\/journal.pone.0001511","article-title":"K+ regulator KCR1 suppresses heart rhythm by modulating the pacemaker current If","volume":"3","author":"Michels","year":"2008","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2025.03.029_bib0040","article-title":"Localization of f-channels to caveolae mediaties specific beta2-adrenergic receptor modulation of rate in sinoatrial myocytes","volume":"42","author":"Barturi","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0041","first-page":"666","article-title":"Cardiovascular actions of 5,6-dimethoxy-2-(3-[alpha-(3,4-dimethoxy)phenylethyl)-methylamino] propyl)phthalimidine (AQ-A 39), a specific bradycardiac agent","volume":"31","author":"Dammgen","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"10.1053\/j.jvca.2025.03.029_bib0042","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/jm00185a013","article-title":"Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site","volume":"23","author":"Stahle","year":"1980","journal-title":"J Med Chem"},{"issue":"Suppl L","key":"10.1053\/j.jvca.2025.03.029_bib0043","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurheartj\/8.suppl_L.5","article-title":"Editorial: History of \u2018specific bradycardic agents","volume":"8","author":"Kobinger","year":"1987","journal-title":"Eur Heart J"},{"issue":"Suppl L","key":"10.1053\/j.jvca.2025.03.029_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/eurheartj\/8.suppl_L.7","article-title":"Specific bradycardic agents\u2014A novel pharmacological class?","volume":"8","author":"Kobinger","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0014-2999(81)90270-3","article-title":"AQ-A 39 (5,6-dimethoxy-2-[3[[alpha-(3,4-dimethoxy)-phenylethyl]methamino]propyl]phtalimidine), a specific bradycardic agent with direct action on the heart","volume":"72","author":"Kobinger","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0046","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0014-2999(79)90005-0","article-title":"Cardiovascular actions of N-allyl-clondine (ST 567). a substance with specific bradycardiac action","volume":"58","author":"Kobinger","year":"1979","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0047","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/oxfordjournals.eurheartj.a061350","article-title":"Alinidine, a new agent which lowers heart rate in patients with angina pectoris","volume":"3","author":"Simoons","year":"1982","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(84)90363-7","article-title":"Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-2-benzazepin-2-on hydrochloride, a new \u201cspecific bradycardic agent","volume":"104","author":"Kobinger","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0049","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0306-4522(94)90602-5","article-title":"Specific bradycardic agents block the hyperpolarization-activated cation current in central neurons","volume":"59","author":"Pape","year":"1994","journal-title":"Neuroscience"},{"key":"10.1053\/j.jvca.2025.03.029_bib0050","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1021\/jm00167a033","article-title":"Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties","volume":"33","author":"Reiffen","year":"1990","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2025.03.029_bib0051","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1021\/jm00107a011","article-title":"Specific bradycardic agents. 2. Heteroaromatic modifications in the side chain of specific bardycardic benzazepinones: Chemistry, pharmacology, and structure-activity relationships","volume":"34","author":"Bomhard","year":"1991","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2025.03.029_bib0052","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00005344-198501000-00012","article-title":"Actions of two new bradycardic agents, AQ-AH 208 and UL-FS 49, on ischemic myocardial perfusion and function","volume":"7","author":"Dammgen","year":"1985","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0053","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00000542-198711000-00015","article-title":"Specific bradycardiac agents, a new therpeutic modality for anesthesiology: Hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs","volume":"67","author":"Riley","year":"1987","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0054","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0735-1097(93)90691-S","article-title":"Effect of zatebradine on contractility, relaxation and coronary blood flow","volume":"21","author":"Breall","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2007-1010191","article-title":"Pharmacologic heart rate reduction: Effect of a novel specific bradycardic agent on the heart","volume":"46","author":"Granetzny","year":"1998","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2025.03.029_bib0056","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejphar.2003.08.083","article-title":"Use-dependent blockage of cardiac pacemaker current (If) by cilobradine and zatebradine","volume":"478","author":"Van Bogaert","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0057","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/ijms21072416","article-title":"Inhibitory effective perturbations of cilobradine (DK-AH269), a blocker of HCN channels, on amplitude and gating of both hyperpolarization-activated cation and delayed-rectifier potassium currents","volume":"21","author":"Lu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.03.029_bib0058","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/mol.105.020701","article-title":"Bradycardic and proarrhythmic properties of sinus node inhibitors","volume":"69","author":"Stieber","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0059","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005344-199810000-00002","article-title":"A double-blind placebo-controlled evaluation of human electrophysiologic effects of zatebradine, a sinus node inhibitor","volume":"32","author":"Chiamvimonvat","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0060","first-page":"791","article-title":"Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria","volume":"8","author":"Lillie","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0061","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-3565(25)12026-0","article-title":"Zatebradine, a specific bradycardiac agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs","volume":"275","author":"Pagel","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0062","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0014-2999(96)00688-7","article-title":"Increases in inotropic state without change in heart rate: combined use of dobutamine and zatebradine in conscious dogs","volume":"316","author":"Hettrick","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0063","series-title":"Kaplan's Cardiac Anesthesia. Perioperative and Critical Care","first-page":"154","article-title":"Coronary physiology","author":"Crystal","year":"2023"},{"key":"10.1053\/j.jvca.2025.03.029_bib0064","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0735-1097(94)90526-6","article-title":"Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium","volume":"23","author":"Wynsen","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0065","first-page":"705","article-title":"Effects of a bradycardic effect on postischemic cardiac recovery in rabbits","volume":"55","author":"Schmitz-Spanke","year":"2004","journal-title":"J Physiol Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0066","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0735-1097(95)80000-7","volume":"26","author":"Frishman","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0067","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S000-2914(99)X0015-0","article-title":"Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators","volume":"79","author":"Glasser","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0068","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00005344-199507000-00008","article-title":"Electromechanical effects of zatebradine in isolated guinea pig cardiac preparations","volume":"26","author":"Perez","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0069","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/01.CIR.94.3.562","article-title":"Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels","volume":"94","author":"Valenzuela","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.bjp.0706998","article-title":"Cellular mechanisms underlying the pharmacological induction of phosphenes","volume":"150","author":"Cervetto","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0071","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00424-001-0723-7","article-title":"Multiple inhibitory effects of zatebradine (UL-FS 49) on the electrophysiological properties of retinal rod photorectors","volume":"443","author":"Satoh","year":"2002","journal-title":"Pflugers Arch"},{"key":"10.1053\/j.jvca.2025.03.029_bib0072","first-page":"95","article-title":"The impact of organic inhibitors of the hyperpolarization activated current (Ih) on the electroretinogram (ERG) of rodents","volume":"142","author":"Maccarone","year":"2004","journal-title":"Arch Ital Biol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0073","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","article-title":"Ivabradine: role in the chronic heart failure armamentarium","volume":"133","author":"Psotka","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0074","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ahj.2006.01.013","volume":"152","author":"Fox","year":"2006","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000112412","article-title":"The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction-baseline characteristics of the study population","volume":"110","author":"Ferrari","year":"2008","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0076","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.03.029_bib0077","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: The Framingham study","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0078","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001626","article-title":"Heart rate at hospital discharge in patients wwith heart failure is associated with mortality and rehospitalization","volume":"4","author":"Laskey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.03.029_bib0079","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0080","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","article-title":"Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy)","volume":"107","author":"Tendera","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0081","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2010.10.125","article-title":"Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL","volume":"146","author":"Ceconi","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0082","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0083","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2013.06.024","volume":"166","author":"Fox","year":"2013","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0084","first-page":"3291","article-title":"Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: An analysis from the SIGNIFY trial","volume":"36","author":"Fox","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0085","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11883-014-0463-8","article-title":"Ivabradine, coronary artery disease, and heart failure: Time for reappraisal","volume":"16","author":"Stulc","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1053\/j.jvca.2025.03.029_bib0086","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ehf2.12012","article-title":"Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure","volume":"1","author":"Clark","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0087","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1517\/14656566.2015.1059423","article-title":"Evaluation of the SIGNIFY trial","volume":"16","author":"Grassi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.jvca.2025.03.029_bib0088","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.conctc.2016.06.003","article-title":"Heart rate modulation in stable coronary artery disease without clinical heart failure: What have we already learned from SIGNIFY?","volume":"4","author":"Perna","year":"2016","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1053\/j.jvca.2025.03.029_bib0089","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effects of ivadradine, a direct sinus node inhibitor, on heart rate in healthy volunteers","volume":"64","author":"Ragueneau","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCOUTCOMES.115.002091","article-title":"Quality of life with ivabradine in patients with angina pectoris: The study assessing the morbidity-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease quality of life substudy","volume":"9","author":"Tendera","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.jvca.2025.03.029_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/0140-6736(90)90551-F","article-title":"Pathophysiology of angina","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.03.029_bib0092","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cardfail.2009.05.013","article-title":"Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: Preliminary findings","volume":"15","author":"Fasullo","year":"2009","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0093","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1755-5922.12266","article-title":"Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction\u2014\u201cexpanding arena for ivabradine","volume":"35","author":"Priti","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0094","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijcard.2017.02.046","article-title":"Ivabradine in acute coronary syndromes: protection beyond heart rate","volume":"236","author":"Niccoli","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43044-023-00351-8","article-title":"Ivabradine in patients with acute ST-elevation myocardial infarction: A meta-analysis of randomized controlled trials","volume":"75","author":"Sasmita","year":"2023","journal-title":"Egypt Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0096","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","article-title":"Predischarge initiation of ivabradine in the management of heart failure: Results of the PRIME-HF trial","volume":"233","author":"Mentz","year":"2020","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0097","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: A preliminary randomized prospective study","volume":"36","author":"Barilla","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1053\/j.jvca.2025.03.029_bib0098","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000322905","article-title":"Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis","volume":"117","author":"Busseuil","year":"2010","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0099","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.111.183913","article-title":"Role of heart rate reduction in the prevention of experimental heart failure: Comparison between If-channel blockade and beta-receptor blockade","volume":"59","author":"Becher","year":"2012","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2025.03.029_bib0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.106.118109","article-title":"Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure","volume":"321","author":"Cheng","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0101","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictor of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0103","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-018-9696-x","article-title":"Novel drugs for heart rate control in heart failure","volume":"23","author":"Bielecka-Dabrowa","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0104","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in the CIBIS II trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0105","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.03.029_bib0107","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being of patients with heart failure: The Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HT). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.03.029_bib0108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.03.029_bib0109","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacc.2008.04.028","article-title":"Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"52","author":"Abraham","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0110","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart rate with reduced ejection fraction: A review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.03.029_bib0111","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 Update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/eurheartj\/ehi162","article-title":"Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic review","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise tolerance in patients with heart failure (the CARVIVA trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","article-title":"Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: The Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)","volume":"12","author":"Swedberg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0117","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with the European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0118","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: Results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0119","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","article-title":"Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients","volume":"62","author":"Reil","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0120","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1152\/jappl.1993.74.5.2566","article-title":"Computation of aortic flow from pressure in humans using a nonlinear, three element model","volume":"74","author":"Wesseling","year":"1993","journal-title":"J Appl Physiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0121","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0122","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ehf2.12513","article-title":"Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m","volume":"6","author":"Bouabdallaoui","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0123","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with I(f) inhibitor ivabradine trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0124","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000380812","article-title":"Effect of combining ivabradine and beta-blockers: Focus on the use of carvelilol in the SHIFT population","volume":"131","author":"Bocchi","year":"2015","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradinee on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0126","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","article-title":"Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials","volume":"34","author":"Fox","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0127","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure to blood pressure level in SHIFT","volume":"16","author":"Komajda","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0128","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.347","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: An analysis from the SHIFT trial","volume":"17","author":"Komajda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0129","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2013.10.068","article-title":"Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study","volume":"170","author":"Tavazzi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0131","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.amjcard.2015.09.029","article-title":"Influence of cardiovascular and noncardiovascular co-morbidities on outcome and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT trial)","volume":"116","author":"Bohm","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0132","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.1021","article-title":"Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: Findings from SHIFT","volume":"20","author":"Bohm","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0133","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ehf2.12240","article-title":"Argentina Chile and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: A post hoc analysis of the SHIFT trial","volume":"5","author":"Bocchi","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0134","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of ivabradine in Japanese patients with chronic heart failure\u2014J-SHIFT study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jacc.2022.05.027","article-title":"Sustained-release ivabradine hemisulfate in patients with systolic heart failure","volume":"80","author":"Ye","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0136","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.jvca.2020.07.016","article-title":"Heart failure with preserved ejection fraction: A comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications","volume":"35","author":"Pagel","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.03.029_bib0137","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ejhf.1708","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: Implications for incident and prevalent heart failure","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.03.029_bib0138","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0139","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/eurheartj\/ehs218","article-title":"Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction","volume":"34","author":"Reil","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: A randomized trial","volume":"62","author":"Kosmala","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0141","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","article-title":"Effect of selective heart rate slowing in heart failure with preserved ejection fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0142","first-page":"1504","article-title":"Heart rate in heart failure with preserved ejection fraction: Target of marker?","volume":"19","author":"Kalogeropoulos","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0143","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10741-017-9660-1","article-title":"Pharmacological heart rate lowering in patients with a preserved ejection fraction\u2014Review of a failing concept","volume":"23","author":"Meyer","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0144","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/europace\/euy128","article-title":"Inappropriate sinus tachycardia","volume":"21","author":"Olshansky","year":"2019","journal-title":"Europace"},{"key":"10.1053\/j.jvca.2025.03.029_bib0145","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/phar.2391","article-title":"Beyond heart failure and ischemic heart disease: A scoping review of novel uses of ivabradine in adults","volume":"40","author":"Hellenbart","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.03.029_bib0146","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.31083\/j.rcm2204139","article-title":"Inappropriate sinus tachycardia: A review","volume":"22","author":"Ali","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0147","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjcard.2022.07.041","article-title":"Targeted treatment of inappropriate sinoatrial node tachycardia based on electrophysiological and structure mechanisms","volume":"183","author":"de Asmundis","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0148","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305135120","article-title":"A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family","volume":"120","author":"Camara-Checa","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.jvca.2025.03.029_bib0149","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10840-015-0034-0","article-title":"Conventional management of inappropriate sinus tachycardia","volume":"46","author":"Olshansky","year":"2016","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0150","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jce.14942","article-title":"Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: A single-center experience","volume":"32","author":"Shabtaie","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0151","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/107424840300800202","article-title":"Sinus tachyarrhythmias and specific bradycardic agents: A marriage made in heaven?","volume":"8","author":"Yusuf","year":"2003","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0152","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000111931","article-title":"Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: A case report","volume":"110","author":"Schulze","year":"2008","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0153","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1540-8167.2009.01699.x","article-title":"Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction","volume":"21","author":"Sette","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0154","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00210-010-0565-y","article-title":"Ivabradine in patients with inappropriate sinus tachycardia","volume":"382","author":"Zellerhoff","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0155","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.hrthm.2010.05.034","article-title":"Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia","volume":"7","author":"Calo","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1053\/j.jvca.2025.03.029_bib0156","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10840-015-0066-5","article-title":"Treatment of inappropriate sinus tachycardia with ivabradine","volume":"46","author":"Annamaria","year":"2016","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0157","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/pace.12018","article-title":"Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway","volume":"36","author":"Ptaszynski","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0158","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","article-title":"Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: A prospective, randomized, placebo-controlled, double-blind, crossover evaluation","volume":"60","author":"Cappato","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0159","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.03.002","article-title":"2017 ACC\/AHA\/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society","volume":"70","author":"Shen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40256-017-0252-1","article-title":"Ivabradine for treatment of postural orthostatic tachycardia syndrome: A systematic review","volume":"18","author":"Gee","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2025.03.029_bib0161","first-page":"e7868","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: A review of the literature","volume":"12","author":"Tahir","year":"2020","journal-title":"Cureus"},{"key":"10.1053\/j.jvca.2025.03.029_bib0162","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FJC.0000000000001609","article-title":"Ivabradine approved and other uses in clinical practice: A clinical review","volume":"84","author":"Hajiqasemi","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0163","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-med-041818-011630","article-title":"Postural orthostatic tachycardia syndrome: Mechanisms and new therapies","volume":"71","author":"Mar","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0164","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12852","article-title":"Postural orthostatic tachycardia syndrome: Clinical presentation, aetiology, and management","volume":"285","author":"Federowski","year":"2019","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2021.102828","article-title":"Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting\u2014part 1","volume":"235","author":"Vernino","year":"2021","journal-title":"Auton Neurosci"},{"key":"10.1053\/j.jvca.2025.03.029_bib0166","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2024.103232","article-title":"Metabolic targets in postural orthostatic tachycardia syndrome: A short thematic review","volume":"256","author":"Glasgow","year":"2024","journal-title":"Auton Neurosci"},{"key":"10.1053\/j.jvca.2025.03.029_bib0167","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2018.11.059","article-title":"Postural orthostatic tachycardia syndrome: JACC focus seminar","volume":"73","author":"Bryarly","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0168","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102977","article-title":"Pathophysiology and management of postural orthostatic tachycardia syndrome (POTS): A literature review","volume":"50","author":"Ghazal","year":"2025","journal-title":"Curr Prob Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0169","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/FJC.0000000000001432","article-title":"Postural orthostatic tachycardia syndrome after COVID-19: A systematic review of therapeutic interventions","volume":"82","author":"Abbate","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CRD.0000000000000503","article-title":"Postural tachycardia syndrome and COVID-19: Focus on ivabradine therapy","volume":"32","author":"Dixit","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.jvca.2025.03.029_bib0171","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1540-8159.2009.02186.x","article-title":"Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker","volume":"32","author":"Khan","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0172","first-page":"273","article-title":"Use of ivabradine in postural orthostatic tachycardia syndrome","volume":"3","author":"Jamil-Copley","year":"2010","journal-title":"J Atr Fibrillation"},{"key":"10.1053\/j.jvca.2025.03.029_bib0173","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/europace\/euq390","article-title":"Single centre experience of ivabradine in postural orthostatic tachycardia syndrome","volume":"13","author":"McDonald","year":"2011","journal-title":"Europace"},{"key":"10.1053\/j.jvca.2025.03.029_bib0174","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-017-0248-x","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: Preliminary experience in children","volume":"18","author":"Della Donne","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2025.03.029_bib0175","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","article-title":"Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome","volume":"77","author":"Taub","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0176","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1053\/j.jvca.2025.03.029_bib0177","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1053\/j.jvca.2020.02.047","article-title":"Use of ivabradine in the treatment of tachyarrhythmias after surgery for congenital heart disease","volume":"34","author":"Khan","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.03.029_bib0178","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.660855","article-title":"Ivabradine: A potential therapeutic for children with refractory SVT","volume":"8","author":"Younis","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.03.029_bib0179","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacep.2021.01.020","article-title":"Ivabradine versus amiodarone in the management of postoperative junctional ectopic tachycardia: A randomized, open-label, noninferiority study","volume":"7","author":"Arvind","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0180","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","article-title":"Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFY and SHIFT trials","volume":"34","author":"Fox","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.03.029_bib0181","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1053\/j.jvca.2025.03.029_bib0182","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yjmcc.2015.05.009","article-title":"Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4","volume":"85","author":"Lees-Miller","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0183","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de pointes induced by concomitant use of ivabradine and azithromycin: An unexpected dangerous interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0184","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/bja\/73.5.658","article-title":"Midazolam is metabolized by at least three different cytochrome P450 enzymes","volume":"73","author":"Wandel","year":"1994","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.03.029_bib0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/cp.1999.v66.100038001","article-title":"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study","volume":"66","author":"Hamaoka","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.03.029_bib0186","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1213\/00000539-199305000-00022","article-title":"Human alfentanil metabolism by cytochrome P450 3A3\/4. An explanation for the interindividual variability in alfentanil clearance?","volume":"76","author":"Kharasch","year":"1993","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.03.029_bib0187","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00000542-199501000-00026","article-title":"Metabolism of a new local anesthetic, ropivicaine, by human hepatic cytochrome P450","volume":"82","author":"Oda","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.03.029_bib0188","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0950-3501(98)80029-9","article-title":"The role of the cytochrome P450 system in drug interactions in anaesthesia","volume":"12","author":"Friedericy","year":"1998","journal-title":"Bailleres Clin Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0189","unstructured":"United States Food and Drug Administration. Drug development and drug interactions. Table of substrates, inhibitors, and inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Published 2023. Accessed January 18, 2025.."},{"key":"10.1053\/j.jvca.2025.03.029_bib0190","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/aer.AER_175_18","article-title":"Study of attenuation of hemodynamic response to laryngoscopy and endotracheal intubation using intra-oral ivabradine","volume":"13","author":"Arora","year":"2019","journal-title":"Anesth Essays Res"},{"key":"10.1053\/j.jvca.2025.03.029_bib0191","doi-asserted-by":"crossref","first-page":"343","DOI":"10.14740\/jocmr4441","article-title":"Use of preoperative single dose ivabradine for perioperative hemodynamic stabilization during non-cardiac elective surgery under general anaesthesia: A pilot study","volume":"13","author":"Banerjee","year":"2021","journal-title":"J Clin Med Res"},{"key":"10.1053\/j.jvca.2025.03.029_bib0192","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4103\/joacp.joacp_191_23","article-title":"Evaluation of efficacy of oral ivabradine for attenuation of hemodynamic response to intubation in hypertensive surgical patients: Effect on rate pressure product as an index of myocardial oxygen demand","volume":"40","author":"Naithani","year":"2024","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0193","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0003-4975(98)00346-4","article-title":"Inhibition of the pacemaker current: A bradycardic therapy for off-pump coronary operations","volume":"66","author":"Bel","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2025.03.029_bib0194","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/aca.aca_97_22","article-title":"Effect of preoperative ivabradine on hemodynamics during elective off-pump CABG","volume":"26","author":"Virmani","year":"2023","journal-title":"Ann Card Anaesth"},{"key":"10.1053\/j.jvca.2025.03.029_bib0195","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bja.2024.05.020","article-title":"Personalised perioperative dosing of ivabradine in noncardiac surgery: A single-center, randomised, placebo-controlled, double-blind feasibility pilot trial","volume":"133","author":"White","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.03.029_bib0196","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.03.029_bib0197","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028760","article-title":"Ivabradine in the prevention, and reduction in size, of perioperative myocardial injury in patients undergoing orthopedic surgery for acute fracture","volume":"12","author":"Rafiudeen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.03.029_bib0198","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1310\/hpj5009-806","article-title":"Ivabradine","volume":"50","author":"Cada","year":"2015","journal-title":"Hosp Pharm"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025002472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025002472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T22:06:35Z","timestamp":1750543595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025002472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":198,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053077025002472"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.03.029","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. II. Ivabradine, an Inhibitor of the Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}